Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Robert W Sullivan"'
Autor:
Leah Fung, Hans C. Lee, Richard J. Jones, Frank Mercurio, Robert W. Sullivan, Imelda Lam, David I. Stirling, Fazal Shirazi, Jianxuan Zou, Paul Erdman, David Hecht, Hua Wang, Normand Richard, Kyle W. H. Chan, Brooke McElwee, Aparajita Hoskote Chourasia, Elisabet E. Manasanch, Isere Kuiatse, Robert Z. Orlowski, Eduardo Torres
Publikováno v:
Journal of Molecular Medicine. 98:1161-1173
Small molecules targeting the cereblon-containing E3 ubiquitin ligase including thalidomide, lenalidomide, and pomalidomide modulate turnover of downstream client proteins and demonstrate pre-clinical and clinical anti-myeloma activity. Different dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06af628a339051f75823cfd26ea68ed
https://doi.org/10.1007/s00109-020-01943-6
https://doi.org/10.1007/s00109-020-01943-6
Autor:
Donatas Kraskauskas, Cathy A. Swindlehurst, Sayantanee Das, Kyle W. H. Chan, Adolfo G Mauro, Leah Fung, Sahak Hovsepian, Fadi N Salloum, Chad Cain, Arun Samidurai, Laura G. Corral, Robert W. Sullivan, Anindita Das
Publikováno v:
Circulation. 142
Background: Doxorubicin (DOX) is a first-line anticancer drug for the treatment of triple negative breast cancer (TNBC). However, its dose-dependent delayed and progressive cardiotoxicity limits its therapeutic application. NovoMedix (NM922) is a nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e7b44870efc8f76d83255dcb52ab03e
https://doi.org/10.1161/circ.142.suppl_3.17055
https://doi.org/10.1161/circ.142.suppl_3.17055
Publikováno v:
Cancer Research. 80:LB-211
Triple negative breast cancer (TNBC) is highly aggressive and has higher rates of recurrence, resistance, and death than other breast cancers. Ten year survival rate is < 50%. Changes in the tumor stroma create an environment that provides support fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51f958692e6977570c8f925a79fb859c
https://doi.org/10.1158/1538-7445.am2020-lb-211
https://doi.org/10.1158/1538-7445.am2020-lb-211
Autor:
Guy Brachya, Yinon Ben-Neriah, Moshe Oren, Liran I. Shlush, Itay Omer, Amitai Rivlin, Robert W. Sullivan, Eli Pikarsky, Nathali Kaushansky, Li Dansu, Adar Zinger, Frank Mercurio, Ross L. Levine, Eitan Winter, Waleed Minzel, Ido Burstain, Avanthika Venkatachalam, Joseph Vacca, Leah Fung, Eric Hung, Maya Shaham, Irit Snir-Alkalay, Avner Fink, Paul Erdman, Shlomo Elias
Summary CKIα ablation induces p53 activation, and CKIα degradation underlies the therapeutic effect of lenalidomide in a pre-leukemia syndrome. Here we describe the development of CKIα inhibitors, which co-target the transcriptional kinases CDK7 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2440625cc9c49007ec76bcf64decbae
https://europepmc.org/articles/PMC6701634/
https://europepmc.org/articles/PMC6701634/
Autor:
David J. Lefer, Laura G. Corral, Jessica M. Bradley, Zhen Li, Pablo Spaletra, Kyle W. H. Chan, Robert W. Sullivan, Thomas E. Sharp rd, Cathy A. Swindlehurst, Leah Fung, Traci T. Goodchild
Publikováno v:
American journal of physiology. Heart and circulatory physiology. 315(3)
Cardiac fibroblasts are critical mediators of fibrotic remodeling in the failing heart and transform into myofibroblasts in the presence of profibrotic factors such as transforming growth factor-β. Myocardial fibrosis worsens cardiac function, accel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8e90bafbc46d42c8bfcfc9b7835a98a
https://pubmed.ncbi.nlm.nih.gov/30004238
https://pubmed.ncbi.nlm.nih.gov/30004238
Autor:
David I. Stirling, Yinon Ben-Neriah, Imelda Lam, David Hecht, Irit Snir-Alkalay, Paul Erdman, Leah Fung, Kyle W. H. Chan, Frank Mercurio, Robert W. Sullivan, Eduardo Torres, Brooke McElwee, Aparajita Hoskote Chourasia, Normand Richard, Avanthika Venkatachalam
Publikováno v:
Blood. 134:4643-4643
BioTheryx's small-molecule kinase inhibitor, BTX-A51 (the ditosylated salt of A51), has recently received FDA approval of its IND application to initiate a Phase I clinical trial in relapsed or refractory acute myeloid leukemia (AML). A51 (API of BTX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7901d7e81d16150b5040f43fb830384b
https://doi.org/10.1182/blood-2019-131834
https://doi.org/10.1182/blood-2019-131834
Autor:
Robert W. Sullivan, Eduardo Torres, Paul Erdman, Leah Fung, David Hecht, Imelda Lam, Frank Mercurio, Brooke McElwee, Aparajita Hoskote Chourasia, David I. Stirling, Normand Richard, Kyle W. H. Chan
Publikováno v:
Blood. 134:3361-3361
Targeting disease-relevant proteins by exploiting the cells' very own protein homeostasis machinery is the next generation drug discovery platform that has come center stage for treatment of hematological malignancies. We present our novel and unique
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e47590684ddbee080a7c800653f35ab3
https://doi.org/10.1182/blood-2019-131872
https://doi.org/10.1182/blood-2019-131872
Autor:
Jessica M Bradley, Craig M Ziblich, Kazi N Islam, Amanda M Rushing, David J Polhemus, Laura G Corral, Robert W Sullivan, Leah Fung, Kyle W Chan, Cathy A Swindlehurst, David J Lefer
Publikováno v:
Circulation. 132
Background: Cardiac fibroblasts are critical mediators of fibrotic remodeling in the failing heart. These maladaptive structural changes can worsen cardiac function accelerating the progression to decompensated heart failure (HF). We investigated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::81576867a9aeb493b92aadf6f6dfeb7b
https://doi.org/10.1161/circ.132.suppl_3.14309
https://doi.org/10.1161/circ.132.suppl_3.14309
Autor:
Charles Q. Huang, James R. McCarthy, Paul D. Crowe, Raymond S. Gross, John Saunders, Dimitri E. Grigoriadis, Jodene Nelson, Richard Lowe, Brian Dyck, John P. Williams, Dragan Marinkovic, Sam R. J. Hoare, Tim Coon, Robert W. Sullivan, Mustapha Haddach, Said Zamani-Kord, Manisha Moorjani, Zhiqiang Guo, Jane Han Bu, Takung Chen
Publikováno v:
Journal of Medicinal Chemistry. 48:5780-5793
Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochemical properties, new tricyclic CRF(1) an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ed6584cab9355c213297346348adfa0
https://doi.org/10.1021/jm049085v
https://doi.org/10.1021/jm049085v
Autor:
Said Zamani-Kord, Brian Dyck, Zhiqiang Guo, Robert W. Sullivan, Zhiyong Luo, Raymond S. Gross, Manisha Moorjani, Bin-Feng Li, Mustapha Haddach, John E. Tellew, Mehrak Kiankarimi, Marion Lanier, John P. Williams, James R. McCarthy, Dimitri Grigoriadis, Ta Kung Chen, Paul D. Crowe, John Saunders, Xiaohu Zhang, Jonathan Grey
Publikováno v:
Journal of Medicinal Chemistry. 48:5104-5107
The synthesis and SAR studies of tricyclic imidazo[4,5-b]pyridin-2-ones as human corticotropin-releasing factor receptor (CRF(1)) antagonists are discussed herein. Compound 16g was identified as a functional antagonist that inhibited CRF-stimulated c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::815355c45c4d5367cde1ab00c4dece95
https://doi.org/10.1021/jm050384+
https://doi.org/10.1021/jm050384+